US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

1.89

+0.11906.72%

Volume:263.68K

Turnover:487.92K

Market Cap:30.70M

PE:-8.42

High:1.90

Open:1.82

Low:1.78

Close:1.77

Loading ...

Overview Company News Filings

JNJ Halts Development of Depression Drug Over Efficacy Concerns

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs

NetraMark Showcases AI Breakthroughs in Clinical Trials for MDD and Schizophrenia

Cingulate reports safety results from final Phase 3 trials for CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Strategic Adjustments and MDD Focus Drive Buy Rating for Neumora Therapeutics Amid Study Delays

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

ACCESS Newswire

Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

Press Release: Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABVC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.889,"timestamp":1750091870231,"preClose":1.77,"halted":0,"volume":263684,"delay":0,"floatShares":14011099,"shares":16250952,"eps":-0.224214,"marketStatus":"Trading","change":0.119,"latestTime":"06-16 12:38:28 EDT","open":1.82,"high":1.9,"low":1.78,"amount":487923.774124,"amplitude":0.067797,"askPrice":1.89,"askSize":700,"bidPrice":1.88,"bidSize":6857,"shortable":3,"etf":0,"ttmEps":-0.224214,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750104000000},"marketStatusCode":2,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.77,"preHourTrading":{"tag":"盘前","latestPrice":1.81,"preClose":1.77,"latestTime":"09:22 EDT","volume":10110,"amount":18694.800345,"timestamp":1750080164032},"postHourTrading":{"tag":"盘后","latestPrice":1.77,"preClose":1.77,"latestTime":"18:00 EDT","volume":191,"amount":347.8795,"timestamp":1749852055540},"volumeRatio":2.160361},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","floatShares":14011099,"roa":"-10.91%","roe":"-42.42%","lyrEps":-0.419983,"volumeRatio":2.160361,"shares":16250952,"dividePrice":0,"high":1.9,"amplitude":0.067797,"preClose":1.77,"low":1.78,"week52Low":0.4,"pbRate":"5.68","psRate":"60.38","week52High":1.9,"institutionHeld":0,"latestPrice":1.889,"committee":0.814741,"eps":-0.224214,"divideRate":0,"volume":263684,"delay":0,"ttmEps":-0.224214,"open":1.82,"prevYearClose":0.59,"prevWeekClose":1.77,"prevMonthClose":1.37,"prevQuarterClose":1.06,"fiveDayClose":1.62,"twentyDayClose":1.48,"sixtyDayClose":0.665},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABVC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517538457","title":"JNJ Halts Development of Depression Drug Over Efficacy Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2517538457","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517538457?lang=en_us&edition=fundamental","pubTime":"2025-03-08 01:45","pubTimestamp":1741369500,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an adjunctive treatment for major depressive disorder .Though data from the VENTURA program did confirm that the J&J drug was safe and well-tolerated in study participants, the decision to stop developing it for MDD indication is due to ‘insufficient efficacy in the target patient population.’ However, the pharma giant still intends to explore aticaprant’s potential ‘in other areas of high unmet need.’。J&J is currently undergoing full analyses of data from the VENTURA program and intends to share the same at a future medical meeting.This comes as a setback to J&J, which had high expectations for aticaprant in the MDD indication. The company has forecasted generating annual peak sales in the range of $1-$5 billion from the drug in the now-abandoned indication.J&J Reiterates Long-Term View for Innovative Medicine Biz","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jnj-halts-development-depression-drug-174500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0792757196.USD","LU0234572021.USD","IE00BVYPNV92.GBP","SG9999002224.SGD","LU0058720904.USD","ABVC","IE00B1BXHZ80.USD","IE0002141913.USD","LU0098860793.USD","LU1066051225.USD","JNJ","LU1674673691.USD","SG9999001440.SGD","LU1261432733.SGD","IE00BGHQF631.EUR","IE00BFTCPJ56.SGD","IE0002270589.USD","IE00BSNM7G36.USD","LU1057294990.SGD","LU2129689514.USD","IE00BDGV0183.EUR","LU1061106388.HKD","LU0889566641.SGD","LU2505996681.GBP","LU1066051498.USD","LU0795875086.SGD","IE00BJJMRZ35.SGD","LU1267930813.SGD","LU1732800096.USD","NMRA","LU1732799900.SGD","ITCI","LU2112291526.USD","BK4533","LU0122379950.USD","BK4581","LU2468319806.SGD","IE00B19Z3B42.SGD","LU0912757837.SGD","LU0345769631.USD","BK4532","LU0234570918.USD","LU2430703178.SGD","LU2602419157.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1059921491.USD","IE00B19Z3581.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2517191949","title":"AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191949?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:27","pubTimestamp":1741274820,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi .The settlement agreement resolves the patent litigation brought by Axsome on Hikma for submitting an abbreviated new drug application to the FDA, seeking marketing approval for a generic version of Sunosi in the United States. The patent litigation is pending in the United States District Court for the District of New Jersey.Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.Jazz had received approval for Sunosi as a treatment for narcolepsy in 2019.JAZZ is entitled to receive a high single-digit royalty from Axsome on net sales of Sunosi in the United States. AXSM out-licensed its ex-U.S. marketing rights of Sunosi to Pharmanovia in February 2023.In the past year, shares of Axsome have ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsm-settles-sunosi-patent-litigation-152700923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AXSM","LU0823416689.USD","ABVC","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","ANIP","BK4007","BK4585","RIGL","IE00BN0W2T93.GBP","BK4505","BK4533","LU0109394709.USD","JAZZ","ADHD","LU0889565916.HKD","BK4139","BK4532","LU0320765992.SGD"],"gpt_icon":0},{"id":"2517215640","title":"MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517215640?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":"--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet  in Generalized Anxiety Disorder ; 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama--. --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder  in 1H of 2025--. --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--. --Company to host a conference call today at 8:00 a.m. EST--. NEW YORK, March 06, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights.Initiated dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-reports-fourth-quarter-full-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","BK4139","LU0256331488.USD","ODT","APA","ABVC","BK4213","BK4007","BK4585","BK4547","BK4588"],"gpt_icon":0},{"id":"2517921713","title":"ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921713","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921713?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"ABVC plans to allocate significant resources toward constructing \"gigafactories\" in the U.S., for its products. The initial phase of such development represents an estimated investment of USD 120 million. The factories are expected to be built to enable the use of cutting-edge technologies- including vertical farming, hydroponic systems, and AI-driven environmental controls- to cultivate high-value medicinal plants under controlled, pesticide-free conditions. Initially, the goal is to achieve an annual output of over 1,000 metric tons of botanical raw materials, as we plan to design the facility to reduce raw material costs by 30%, enhance product quality, and provide a sustainable, traceable supply chain to support ABVC's botanical-based pharmaceuticals. Together, these projects are expected to significantly expand ABVC's drug manufacturing capacity, create more than 500 new jobs across research, manufacturing and quality control operations, and support projected product sales exceedi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-plans-expand-investment-210100299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4232","R","BK4022","ABVC"],"gpt_icon":1},{"id":"2517408119","title":"NetraMark Showcases AI Breakthroughs in Clinical Trials for MDD and Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2517408119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517408119?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:45","pubTimestamp":1741196753,"startTime":"0","endTime":"0","summary":"An update from NetraMark Holdings ( ($TSE:AIAI) ) is now available. NetraMark Holdings Inc. presented groundbreaking studies at the ISCTM conferenc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/netramark-showcases-ai-breakthroughs-in-clinical-trials-for-mdd-and-schizophrenia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/netramark-showcases-ai-breakthroughs-in-clinical-trials-for-mdd-and-schizophrenia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2516521674","title":"Cingulate reports safety results from final Phase 3 trials for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2516521674","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516521674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097232,"startTime":"0","endTime":"0","summary":"Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CING","ABVC","BK4139"],"gpt_icon":0},{"id":"2516674892","title":"Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674892","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674892?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036578/0/en/Cingulate-Reports-Safety-Results-from-Final-Phase-3-Trials-for-Lead-ADHD-Asset-CTx-1301-On-Track-to-File-for-FDA-Approval-Mid-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4503","BK4139","BK4023","BK4535","ABVC","ADHD","API","BK4007","CING","BK4551"],"gpt_icon":0},{"id":"2516675847","title":"Strategic Adjustments and MDD Focus Drive Buy Rating for Neumora Therapeutics Amid Study Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675847?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:35","pubTimestamp":1741091742,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-mdd-focus-drive-buy-rating-for-neumora-therapeutics-amid-study-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-mdd-focus-drive-buy-rating-for-neumora-therapeutics-amid-study-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","LENZ","NMRA"],"gpt_icon":0},{"id":"2516644669","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516644669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516644669?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:30","pubTimestamp":1741037400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 03, 2025  -- Neuronetics, Inc. , a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company’s common stock  to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635, these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, third and fourth anniversary of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuronetics-reports-inducement-grant-under-213000571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4585","BK4588","IE00BKPKM429.USD","ABVC",".IXIC","LU2210150020.SGD","IE00B3QW5Z07.USD","STIM","NDAQ","LU2210149790.SGD","BK4082","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","BK4139"],"gpt_icon":0},{"id":"2516404545","title":"Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516404545","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516404545?lang=en_us&edition=fundamental","pubTime":"2025-03-03 01:16","pubTimestamp":1740935800,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now.In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.  stands against the other small cap pharma stocks.Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry. Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, the industry might not perform poorly at least in the first half of this year. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-best-171640328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0882574055.USD","BK4599","TQQQ","USJW.SI","USAW.SI","LU0354030511.USD","IE00B1BXHZ80.USD","LU2237443549.SGD","QID","LU2264538146.SGD","LU0708995401.HKD","LU0114720955.EUR","LU0385154629.USD","LU0471298777.SGD","LU2237443978.SGD","LU1280957306.USD","IE00BJT1NW94.SGD","LU1974910355.USD","LLY","IE00BJJMRZ35.SGD","LU0061475181.USD","PSQ","SQQQ","LU0058720904.USD","MNQmain","LU2491049909.HKD","BK4516","LU1868836757.USD","SG9999014898.SGD","LU0820561909.HKD","LU0256863902.USD","LU2237443465.HKD","TSYW.SI","LU1064131342.USD",".IXIC","NQmain","QLD","LU0106261372.USD","LU1712237335.SGD","LU0006306889.USD","LU0823416689.USD","LU2063271972.USD","ABVC","IE00BFTCPJ56.SGD","NVIW.SI","SGXZ31699556.SGD","SUPN","LU1267930730.SGD","LU0320765059.SGD"],"gpt_icon":1},{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1430594728.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU1585245621.USD","XENE","IE00BZ1G4Q59.USD","LU2065171311.SGD","BMRN","LU1066053197.SGD","BK4585","LU0289739699.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4588","BK4578","LU2065170008.USD","IE00BSNM7G36.USD","LU2324357040.USD","LU2065169927.USD","LU0320765992.SGD","LU0058720904.USD","LU2468319806.SGD","LU1066051498.USD","BK4550","LU0823416689.USD","LU0109394709.USD","NBIX","LU0234570918.USD","LU1571399168.USD","LU2089984988.USD","BK4566","BK4568","IE00B7SZLL34.SGD","BK4583","ABVC","LU2065171402.SGD","GILD","IE0002270589.USD","BK4532","LU1839511570.USD","IE00B3T34201.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2514955278","title":"ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514955278","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514955278?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"Japan's biotech industry is valued at over $120 billion, with over 3,000 biotech startups seeking opportunities to expand globally. [1] BioLite Japan seeks to identify high-potential Japanese biotech innovations and guide them through the complex process of international expansion. This includes helping them to secure capital, navigate regulatory frameworks, and form strategic partnerships across Asia and the United States.Taiwan's biomedical sector, valued at $23.5 billion[2], offers a strong foundation for biotech companies looking to expand. BioLite Japan will assist Japanese biotech firms trying to enter Taiwan's thriving biomedical landscape, including the prestigious Hsinchu Biomedical Park. Taiwan's AI-driven healthcare sector, which is growing at 15% annually, will be instrumental in accelerating drug discovery and biotech innovation.\"We are excited to collaborate with ABVC to provide Japanese biotech startups with a clear pathway to international success. By leveraging Taiwa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biolite-japan-implement-strategy-210100384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","BK4022","STRK","BK4585","BK4588","BK4600","ABVC","BK4596","BK4595","BK4232","BK4023","R","BK4139"],"gpt_icon":1},{"id":"2514909967","title":"Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514909967","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514909967?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjectsATLANTA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031992/0/en/Alzamend-Neuro-Announces-Initiation-Date-of-First-Phase-II-Clinical-Trial-of-AL001-to-take-Place-at-Massachusetts-General-Hospital.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","BK4139","ABVC"],"gpt_icon":0},{"id":"2512101274","title":"Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101274","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101274?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:03","pubTimestamp":1739970180,"startTime":"0","endTime":"0","summary":"– Patent supports Alto’s precision approach to improve patient selection –。ALTO-300, also known agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist and is being developed as an adjunctive treatment in the United States for biomarker-characterized patients with MDD who have had an inadequate response to current standard of care antidepressants.\"The granting of this patent underscores our novel approach to patient selection in neuropsychiatric treatment using objective biomarkers,\" said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. \"We are dedicated to developing more effective, targeted treatments for patients with MDD and deepening our understanding of the patient phenotype that is most likely to benefit, based on our unique ALTO-300 biomarker.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-announces-u-patent-130300698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4138","ALTO","ANRO","BK4007","BK4109","BK4139"],"gpt_icon":0},{"id":"2512022151","title":"Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512022151","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512022151?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy, Alzheimer’s disease, BD, MDD, and PTSD subjects. These studies are expected to provide greater clarity on how lithium treatments reach the brain, showcasing AL001’s superior ability to target brain structures while reducing systemic exposures. Nonclinical  studies have already demonstrated that AL001 optimizes brain absorption with lower blood concentration levels when compared to lithium carbonate, suggesting promising human applications. This cutting-edge approach ensures that lithium via AL001 remains effective in the brain with significantly reduced risks of harmful side effects on the kidneys and thyroid. By enabling safer dosing, expanding the therapeutic index and potentially removing the need for lithium therapeutic drug monitoring , AL001 represents a potential groundbreaking advance. These innovatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alzamend-neuro-announces-completion-novel-130000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0082616367.USD","LU2087621335.USD","LU2360106780.USD","LU0820561818.USD","LU2213496289.HKD","TSYW.SI","IE0034235303.USD","IE00BWXC8680.SGD","TSLL","BK4592","IE00BJLML261.HKD","BK4548","LU0689472784.USD","LU2250418816.HKD","LU1548497426.USD","LU0820561909.HKD","LU2357305700.SGD","LU0823411888.USD","LU1551013342.USD","LU2063271972.USD","LU2023250330.USD","LU1435385759.SGD","BK4534","BK4588","LU2360107168.USD","BK4585","LU0097036916.USD","ABVC","LU0823414478.USD","LU2326559502.SGD","LU1429558221.USD","LU2290526834.HKD","LU0077335932.USD","BK4511","BK4516","IE00BSNM7G36.USD","SG9999015986.USD","LU2471134796.USD","LU1852331112.SGD","BK4551","LU2602419157.SGD","TSLA","ALZN","BK4543","LU0345770993.USD","LU2756315318.SGD","BK4581","LU0198837287.USD","LU1861558580.USD","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2512156706","title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2512156706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512156706?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth. Auvelity 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth. Symbravo approved in the U.S. for the acute treatment of migraine with or without aura in adults. Total net product revenues were $118.8 million and $385.7 million for the fourth quarter and full year of 2024, representing 66% and 88% year-over-year growth, respectively. Total net product revenues for the comparable periods in 2023 were $71.5 million and $204.9 million, respectively.Auvelity net product sales were $92.6 million and $291.4 million for the fourth quarter and full year of 2024, representing 89% and 124% year-over-year growth, respectively. Auvelity net product sales for the comparable periods in 2023 were $49.0 million and $130.1 million, respectively.Sunosi net product revenues w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-therapeutics-reports-fourth-quarter-120000921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4585","BK4505","BK4007","BK4139","ADHD","AXSM","BK4135","CNS"],"gpt_icon":0},{"id":"2511586749","title":"This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511586749","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511586749?lang=en_us&edition=fundamental","pubTime":"2025-02-16 21:45","pubTimestamp":1739713500,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics settled a patent litigation lawsuit that posed a significant risk to its prospects.The biotech also has a strengthening lineup and several exciting late-stage pipeline programs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/16/this-stock-is-already-up-51-in-2025-is-it-too-late/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["ADHD","ABVC","BK4139"],"gpt_icon":0},{"id":"2511580225","title":"Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580225","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580225?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:03","pubTimestamp":1739394180,"startTime":"0","endTime":"0","summary":"First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023. Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time. DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.Pediatric Portfolio  net revenue increased 86% sequentially to $2.4 million versus $1.3 million in Q1 fiscal 2025, reflecting positive effects from recently implemented return-to-growth plan for the pediatric product line. Pediatric Portfolio net revenue increased 12% compared to Q2 fiscal 2024.ADHD Portfolio  net revenue increased 16% sequentially to $13.8 million versus $11.9 million in Q1 fiscal 2025 after adjusting for a one-time vendor agreement positively impacting Q1 fiscal 2025 net revenue by $3.3 million.\"This positive commercial momentum paralle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-reports-fiscal-2025-210300699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AYTU","ADHD","BK4007","BK4139","ABVC"],"gpt_icon":0},{"id":"2510372205","title":"Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2510372205","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510372205?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:30","pubTimestamp":1739367000,"startTime":"0","endTime":"0","summary":"BioKey, a wholly owned subsidiary of ABVC, has built considerable confidence in its product and gained traction in the Asian market. We believe the surge in orders for Maitake BLEX 404 from Asia is due to an increase in healthcare professionals' and patients' recognition of the product's potential to enhance cancer treatment effectiveness while boosting the immune system. The rising demand for this product presents a promising opportunity for revenue generation.BioLive's event highlighted ABVC and BioKey's commitment to providing innovative and effective therapies. It also stressed the significance of integrating cancer treatment with immunity-boosting methods. ABVC continues to focus on expanding its product portfolio and entering new markets to address the growing demand for novel healthcare solutions.Generative AI for Drug Discovery: By adopting generative AI models similar to NVIDIA's BioNeMo framework, BioKey aims to accelerate the design and optimization of novel drug candidates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-market-response-asia-fuels-133000808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USD","ABVC"],"gpt_icon":0},{"id":"2510842596","title":"Press Release: Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2510842596","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510842596?lang=en_us&edition=fundamental","pubTime":"2025-02-11 10:48","pubTimestamp":1739242080,"startTime":"0","endTime":"0","summary":"- Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder  -. - PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies  and a long-term extension study , with anticipated combined enrollment of approximately 550 patients -. - APPROACH has been initiated and will enroll 220 participants at more than 40 clinical sites in the United States and Europe -. - Upcoming milestones include topline efficacy data readout from CYB004 Phase 2 study in general anxiety disorder and initiation of EXTEND and EMBRACE pivotal studies of CYB003 around mid-year 2025 -. - CYB003 in development for MDD has a total addressable market of >300 million people worldwide -. \"Our expanded drug development team has decades of experience overseeing therapeutics through the regulatory process through to launch and are well-versed in the complexities of this type ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4555","TM","BK4604","BK4585","BK4588","BK4099","03160","ABVC"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":90,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-30","symbol":"ABVC","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745985600000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-04-15","symbol":"ABVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1744689600000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2024-11-14","symbol":"ABVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.02},{"market":"US","date":"2024-08-14","symbol":"ABVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2024-05-17","symbol":"ABVC","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715918400000,"reportTimeType":"post","actualEps":-0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABVC","date":"2025-06-13","current":-10.328685,"percent":0.243506,"low":-22.659095,"twenty":-11.690443,"median":-1.615552,"eighty":-0.794817,"high":-0.260274,"avg":-5.517963,"sd":5.90537,"marketCap":30064261},"quantilePoints":[{"date":"2020-06-19","current":-15.563236,"twenty":-104.984049,"median":-70.569383,"eighty":-16.368319,"marketCap":56677821},{"date":"2020-06-26","current":-15.563236,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":56677821},{"date":"2020-07-02","current":-14.066248,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":57638463},{"date":"2020-07-10","current":-14.066248,"twenty":-104.984049,"median":-70.569383,"eighty":-15.82702,"marketCap":57638463},{"date":"2020-07-17","current":-15.472873,"twenty":-104.984049,"median":-70.569383,"eighty":-15.731773,"marketCap":63402309},{"date":"2020-07-24","current":-17.58281,"twenty":-104.984049,"median":-64.954263,"eighty":-15.762085,"marketCap":72048078},{"date":"2020-07-31","current":-18.52056,"twenty":-104.984049,"median":-64.198981,"eighty":-15.771827,"marketCap":75890642},{"date":"2020-08-07","current":-17.817247,"twenty":-104.984049,"median":-60.422571,"eighty":-15.816469,"marketCap":73008719},{"date":"2020-08-14","current":-14.118204,"twenty":-104.984049,"median":-58.912006,"eighty":-15.816469,"marketCap":76088142},{"date":"2020-08-21","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.601069,"marketCap":77051284},{"date":"2020-08-28","current":-12.867224,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":69346155},{"date":"2020-09-04","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-11","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":76088142},{"date":"2020-09-18","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-25","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.299453,"marketCap":76088142},{"date":"2020-10-02","current":-14.654339,"twenty":-104.984049,"median":-47.962314,"eighty":-14.943492,"marketCap":78977566},{"date":"2020-10-09","current":-14.887513,"twenty":-104.984049,"median":-47.962314,"eighty":-14.873601,"marketCap":80234224},{"date":"2020-10-16","current":-15.910707,"twenty":-104.984049,"median":-47.962314,"eighty":-14.887513,"marketCap":85748593},{"date":"2020-10-23","current":-15.522641,"twenty":-104.984049,"median":-47.962314,"eighty":-14.957404,"marketCap":83657164},{"date":"2020-10-30","current":-15.134575,"twenty":-104.984049,"median":-46.033619,"eighty":-15.082344,"marketCap":81565734},{"date":"2020-11-06","current":-15.199238,"twenty":-104.984049,"median":-46.033619,"eighty":-15.134575,"marketCap":81914224},{"date":"2020-11-13","current":-15.009247,"twenty":-104.984049,"median":-43.698955,"eighty":-14.957404,"marketCap":80890296},{"date":"2020-11-20","current":-13.64563,"twenty":-104.984049,"median":-39.895803,"eighty":-14.839343,"marketCap":82154224},{"date":"2020-11-27","current":-14.327911,"twenty":-104.984049,"median":-39.895803,"eighty":-14.654339,"marketCap":86261935},{"date":"2020-12-04","current":-14.498482,"twenty":-104.984049,"median":-39.895803,"eighty":-14.484769,"marketCap":87288863},{"date":"2020-12-11","current":-15.351334,"twenty":-104.984049,"median":-38.369814,"eighty":-14.475627,"marketCap":92423502},{"date":"2020-12-18","current":-17.057037,"twenty":-104.984049,"median":-37.594122,"eighty":-14.484769,"marketCap":102692780},{"date":"2020-12-24","current":-17.739319,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":106800491},{"date":"2020-12-31","current":-17.398178,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":104746635},{"date":"2021-01-08","current":-20.052297,"twenty":-104.984049,"median":-36.67345,"eighty":-14.549617,"marketCap":120725895},{"date":"2021-01-15","current":-21.65648,"twenty":-104.984049,"median":-34.580924,"eighty":-14.654339,"marketCap":130383966},{"date":"2021-01-22","current":-21.255434,"twenty":-104.984049,"median":-33.757987,"eighty":-14.654339,"marketCap":127969448},{"date":"2021-01-29","current":-20.052297,"twenty":-104.984049,"median":-33.757987,"eighty":-14.666109,"marketCap":120725895},{"date":"2021-02-05","current":-19.851774,"twenty":-104.984049,"median":-33.757987,"eighty":-14.751318,"marketCap":119518636},{"date":"2021-02-12","current":-19.450728,"twenty":-104.984049,"median":-32.897231,"eighty":-14.809783,"marketCap":117104118},{"date":"2021-02-19","current":-20.052297,"twenty":-104.984049,"median":-32.897231,"eighty":-14.839343,"marketCap":120725895},{"date":"2021-02-26","current":-17.646021,"twenty":-104.984049,"median":-32.530424,"eighty":-14.873601,"marketCap":106238787},{"date":"2021-03-05","current":-17.646021,"twenty":-104.984049,"median":-31.609752,"eighty":-14.887513,"marketCap":106238787},{"date":"2021-03-12","current":-18.047067,"twenty":-104.984049,"median":-30.689079,"eighty":-14.920184,"marketCap":108653305},{"date":"2021-03-19","current":-10.850476,"twenty":-104.984049,"median":-30.689079,"eighty":-14.839343,"marketCap":106238787},{"date":"2021-03-26","current":-10.973777,"twenty":-104.984049,"median":-30.437981,"eighty":-14.654339,"marketCap":107446046},{"date":"2021-04-01","current":-11.097077,"twenty":-104.984049,"median":-30.103498,"eighty":-14.498482,"marketCap":108653305},{"date":"2021-04-09","current":-10.850476,"twenty":-104.984049,"median":-30.103498,"eighty":-14.386997,"marketCap":106238787},{"date":"2021-04-16","current":-10.850476,"twenty":-104.984049,"median":-29.613533,"eighty":-14.327911,"marketCap":106238787},{"date":"2021-04-23","current":-11.097077,"twenty":-104.984049,"median":-28.765565,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-04-30","current":-11.097077,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-05-07","current":-11.46698,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":112275082},{"date":"2021-05-14","current":-13.730013,"twenty":-104.984049,"median":-27.28369,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-21","current":-13.730013,"twenty":-104.984049,"median":-26.65832,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-28","current":-13.730013,"twenty":-103.326706,"median":-26.132665,"eighty":-14.118204,"marketCap":132798484},{"date":"2021-06-04","current":-13.355558,"twenty":-100.840692,"median":-25.838836,"eighty":-14.118204,"marketCap":129176707},{"date":"2021-06-11","current":-12.981103,"twenty":-100.840692,"median":-25.62158,"eighty":-14.066248,"marketCap":125554930},{"date":"2021-06-18","current":-11.857738,"twenty":-100.840692,"median":-25.489795,"eighty":-14.066248,"marketCap":114689600},{"date":"2021-06-25","current":-12.48183,"twenty":-100.840692,"median":-23.923098,"eighty":-13.947524,"marketCap":120725895},{"date":"2021-07-02","current":-11.233647,"twenty":-100.840692,"median":-23.282,"eighty":-13.770344,"marketCap":108653305},{"date":"2021-07-09","current":-12.48183,"twenty":-100.840692,"median":-22.944579,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-16","current":-12.48183,"twenty":-100.840692,"median":-22.775869,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-23","current":-12.357012,"twenty":-100.840692,"median":-22.633127,"eighty":-13.64563,"marketCap":119518636},{"date":"2021-07-30","current":-12.357585,"twenty":-100.840692,"median":-22.438449,"eighty":-13.64563,"marketCap":119524184},{"date":"2021-08-06","current":-8.290388,"twenty":-100.840692,"median":-22.020758,"eighty":-13.355558,"marketCap":80185717},{"date":"2021-08-13","current":-5.99167,"twenty":-100.840692,"median":-21.65648,"eighty":-13.337149,"marketCap":58684815},{"date":"2021-08-20","current":-5.242711,"twenty":-100.840692,"median":-21.054911,"eighty":-13.23074,"marketCap":51349213},{"date":"2021-08-27","current":-7.670371,"twenty":-100.840692,"median":-20.611957,"eighty":-13.105921,"marketCap":75126681},{"date":"2021-09-03","current":-8.393504,"twenty":-100.840692,"median":-20.536178,"eighty":-12.981103,"marketCap":82209331},{"date":"2021-09-10","current":-8.290199,"twenty":-100.840692,"median":-20.327641,"eighty":-12.731467,"marketCap":81197524},{"date":"2021-09-17","current":-7.386283,"twenty":-100.840692,"median":-20.25282,"eighty":-12.48183,"marketCap":72344211},{"date":"2021-09-24","current":-6.404889,"twenty":-100.840692,"median":-20.249018,"eighty":-12.48183,"marketCap":62732043},{"date":"2021-10-01","current":-5.862539,"twenty":-100.840692,"median":-20.143991,"eighty":-12.48183,"marketCap":57420056},{"date":"2021-10-08","current":-5.578452,"twenty":-96.807064,"median":-20.052297,"eighty":-12.48183,"marketCap":54637586},{"date":"2021-10-15","current":-6.998891,"twenty":-95.798657,"median":-20.052297,"eighty":-12.48183,"marketCap":68549935},{"date":"2021-10-22","current":-6.379063,"twenty":-95.798657,"median":-20.02901,"eighty":-12.357012,"marketCap":62479092},{"date":"2021-10-29","current":-6.885086,"twenty":-95.798657,"median":-20.005723,"eighty":-12.332048,"marketCap":67435282},{"date":"2021-11-05","current":-10.164989,"twenty":-93.770452,"median":-19.95676,"eighty":-12.112235,"marketCap":99559965},{"date":"2021-11-12","current":-8.999403,"twenty":-93.263401,"median":-19.851774,"eighty":-11.72383,"marketCap":88143755},{"date":"2021-11-19","current":-9.556177,"twenty":-93.263401,"median":-19.851774,"eighty":-11.230993,"marketCap":93218994},{"date":"2021-11-26","current":-9.294762,"twenty":-93.263401,"median":-19.851774,"eighty":-11.139591,"marketCap":90668931},{"date":"2021-12-03","current":-8.510516,"twenty":-93.263401,"median":-19.450728,"eighty":-11.097077,"marketCap":83018740},{"date":"2021-12-10","current":-10.108053,"twenty":-90.465498,"median":-19.450728,"eighty":-11.097077,"marketCap":98602462},{"date":"2021-12-17","current":-10.398515,"twenty":-88.60023,"median":-19.450728,"eighty":-11.097077,"marketCap":101435866},{"date":"2021-12-23","current":-10.950391,"twenty":-88.60023,"median":-19.250205,"eighty":-11.042884,"marketCap":106819334},{"date":"2021-12-31","current":-9.846638,"twenty":-88.60023,"median":-18.803806,"eighty":-10.973777,"marketCap":96052398},{"date":"2022-01-07","current":-9.90473,"twenty":-88.60023,"median":-18.754997,"eighty":-10.850476,"marketCap":96619079},{"date":"2022-01-14","current":-9.556177,"twenty":-88.60023,"median":-18.687731,"eighty":-10.850476,"marketCap":93218994},{"date":"2022-01-21","current":-7.900547,"twenty":-88.60023,"median":-18.539338,"eighty":-10.850476,"marketCap":77068591},{"date":"2022-01-28","current":-7.174394,"twenty":-88.60023,"median":-18.52056,"eighty":-10.712213,"marketCap":69985081},{"date":"2022-02-04","current":-7.319625,"twenty":-88.60023,"median":-18.401426,"eighty":-10.554554,"marketCap":71401783},{"date":"2022-02-11","current":-7.668178,"twenty":-88.60023,"median":-18.286122,"eighty":-10.404324,"marketCap":74801868},{"date":"2022-02-18","current":-7.348671,"twenty":-88.60023,"median":-18.220695,"eighty":-10.343792,"marketCap":71685123},{"date":"2022-02-25","current":-7.116302,"twenty":-88.60023,"median":-18.188702,"eighty":-10.164989,"marketCap":69418400},{"date":"2022-03-04","current":-7.116302,"twenty":-88.60023,"median":-18.047067,"eighty":-9.98737,"marketCap":69418400},{"date":"2022-03-11","current":-6.622518,"twenty":-88.60023,"median":-18.047067,"eighty":-9.875684,"marketCap":64601613},{"date":"2022-03-18","current":-6.564425,"twenty":-88.60023,"median":-17.909889,"eighty":-9.788546,"marketCap":64034932},{"date":"2022-03-25","current":-7.029163,"twenty":-88.60023,"median":-17.850261,"eighty":-9.704796,"marketCap":68568379},{"date":"2022-04-01","current":-6.339112,"twenty":-88.60023,"median":-17.739319,"eighty":-9.704796,"marketCap":81386671},{"date":"2022-04-08","current":-6.31572,"twenty":-88.60023,"median":-17.732346,"eighty":-9.704796,"marketCap":81086351},{"date":"2022-04-14","current":-5.894672,"twenty":-88.60023,"median":-17.680293,"eighty":-9.60846,"marketCap":75680594},{"date":"2022-04-22","current":-5.754323,"twenty":-88.60023,"median":-17.646021,"eighty":-9.54452,"marketCap":73878675},{"date":"2022-04-29","current":-5.590582,"twenty":-88.60023,"median":-17.646021,"eighty":-9.360688,"marketCap":71776436},{"date":"2022-05-06","current":-5.766019,"twenty":-88.60023,"median":-17.646021,"eighty":-9.252091,"marketCap":74028835},{"date":"2022-05-13","current":-5.2631,"twenty":-88.60023,"median":-17.58281,"eighty":-9.119715,"marketCap":67571959},{"date":"2022-05-20","current":-3.799171,"twenty":-88.60023,"median":-17.545855,"eighty":-9.098246,"marketCap":67267162},{"date":"2022-05-27","current":-3.527801,"twenty":-88.60023,"median":-17.467267,"eighty":-9.097299,"marketCap":62462364},{"date":"2022-06-03","current":-3.744897,"twenty":-88.60023,"median":-17.373275,"eighty":-9.093511,"marketCap":66306202},{"date":"2022-06-10","current":-1.628216,"twenty":-88.60023,"median":-17.227608,"eighty":-8.989743,"marketCap":28828783},{"date":"2022-06-17","current":-1.764263,"twenty":-88.60023,"median":-17.146548,"eighty":-8.906096,"marketCap":31237588},{"date":"2022-06-24","current":-1.790857,"twenty":-88.60023,"median":-17.057037,"eighty":-8.85907,"marketCap":31708458},{"date":"2022-07-01","current":-1.82722,"twenty":-88.60023,"median":-17.057037,"eighty":-8.794971,"marketCap":32352301},{"date":"2022-07-08","current":-1.881494,"twenty":-88.60023,"median":-16.871014,"eighty":-8.794971,"marketCap":33313261},{"date":"2022-07-15","current":-1.415282,"twenty":-88.60023,"median":-16.641799,"eighty":-8.791309,"marketCap":25058619},{"date":"2022-07-22","current":-1.4189,"twenty":-88.60023,"median":-16.368319,"eighty":-8.790393,"marketCap":25122683},{"date":"2022-07-29","current":-1.175934,"twenty":-88.60023,"median":-16.201757,"eighty":-8.70552,"marketCap":20820788},{"date":"2022-08-05","current":-1.14735,"twenty":-88.60023,"median":-16.10474,"eighty":-8.638835,"marketCap":20314682},{"date":"2022-08-12","current":-1.212116,"twenty":-88.60023,"median":-15.910707,"eighty":-8.55118,"marketCap":21461427},{"date":"2022-08-19","current":-1.600085,"twenty":-88.60023,"median":-15.82702,"eighty":-8.491696,"marketCap":28150574},{"date":"2022-08-26","current":-1.546748,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":27212221},{"date":"2022-09-02","current":-1.875961,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":33004121},{"date":"2022-09-09","current":-2.023095,"twenty":-88.60023,"median":-15.82702,"eighty":-8.340059,"marketCap":35592680},{"date":"2022-09-16","current":-1.3426,"twenty":-88.60023,"median":-15.800641,"eighty":-8.303464,"marketCap":23620596},{"date":"2022-09-23","current":-1.680089,"twenty":-88.60023,"median":-15.762085,"eighty":-8.21272,"marketCap":29558103},{"date":"2022-09-30","current":-1.618476,"twenty":-88.60023,"median":-15.716674,"eighty":-8.036784,"marketCap":28474144},{"date":"2022-10-07","current":-1.626753,"twenty":-88.60023,"median":-15.610527,"eighty":-7.747849,"marketCap":28619750},{"date":"2022-10-14","current":-1.287424,"twenty":-88.60023,"median":-15.563236,"eighty":-7.670371,"marketCap":22649887},{"date":"2022-10-21","current":-1.324208,"twenty":-88.60023,"median":-15.563236,"eighty":-7.581872,"marketCap":23297027},{"date":"2022-10-28","current":-1.359888,"twenty":-88.60023,"median":-15.563236,"eighty":-7.479591,"marketCap":23924752},{"date":"2022-11-04","current":-1.348301,"twenty":-88.60023,"median":-15.563236,"eighty":-7.430234,"marketCap":23720903},{"date":"2022-11-11","current":-1.327151,"twenty":-88.60023,"median":-15.563236,"eighty":-7.386283,"marketCap":23348798},{"date":"2022-11-18","current":-1.231758,"twenty":-88.60023,"median":-15.563236,"eighty":-7.319625,"marketCap":24008880},{"date":"2022-11-25","current":-1.245038,"twenty":-88.60023,"median":-15.522641,"eighty":-7.302197,"marketCap":24267736},{"date":"2022-12-02","current":-1.269773,"twenty":-88.60023,"median":-15.497757,"eighty":-7.288183,"marketCap":24749855},{"date":"2022-12-09","current":-1.228438,"twenty":-88.60023,"median":-15.445794,"eighty":-7.272153,"marketCap":23944166},{"date":"2022-12-16","current":-1.162036,"twenty":-88.60023,"median":-15.329372,"eighty":-7.261532,"marketCap":22649887},{"date":"2022-12-23","current":-1.145435,"twenty":-88.60023,"median":-15.299453,"eighty":-7.226677,"marketCap":22326317},{"date":"2022-12-30","current":-1.037532,"twenty":-88.60023,"median":-15.199238,"eighty":-7.174394,"marketCap":20223113},{"date":"2023-01-06","current":-1.512141,"twenty":-88.133914,"median":-15.199238,"eighty":-7.100329,"marketCap":29473974},{"date":"2023-01-13","current":-1.435777,"twenty":-86.576754,"median":-15.134575,"eighty":-6.953369,"marketCap":27985521},{"date":"2023-01-20","current":-1.29484,"twenty":-85.538648,"median":-15.003998,"eighty":-6.821454,"marketCap":25238445},{"date":"2023-01-27","current":-1.261473,"twenty":-85.538648,"median":-14.852734,"eighty":-6.739858,"marketCap":24588070},{"date":"2023-02-03","current":-1.167182,"twenty":-85.538648,"median":-14.654339,"eighty":-6.646897,"marketCap":22750194},{"date":"2023-02-10","current":-1.245038,"twenty":-70.569383,"median":-14.475627,"eighty":-6.564425,"marketCap":24267736},{"date":"2023-02-17","current":-1.203539,"twenty":-70.569383,"median":-14.327911,"eighty":-6.471848,"marketCap":23458844},{"date":"2023-02-24","current":-1.161758,"twenty":-70.569383,"median":-14.296916,"eighty":-6.418638,"marketCap":22644477},{"date":"2023-03-03","current":-1.170116,"twenty":-70.569383,"median":-14.296916,"eighty":-6.368733,"marketCap":22807387},{"date":"2023-03-10","current":-0.98808,"twenty":-70.569383,"median":-14.296916,"eighty":-6.32741,"marketCap":19259209},{"date":"2023-03-17","current":-1.002957,"twenty":-70.569383,"median":-14.296916,"eighty":-6.222154,"marketCap":19549189},{"date":"2023-03-24","current":-1.019673,"twenty":-70.569383,"median":-14.118204,"eighty":-6.090777,"marketCap":19875009},{"date":"2023-03-31","current":-1.069821,"twenty":-70.569383,"median":-14.118204,"eighty":-5.965645,"marketCap":20852468},{"date":"2023-04-06","current":-1.043077,"twenty":-70.569383,"median":-14.066248,"eighty":-5.910288,"marketCap":20331189},{"date":"2023-04-14","current":-1.321345,"twenty":-64.954263,"median":-14.066248,"eighty":-5.744966,"marketCap":21700767},{"date":"2023-04-21","current":-1.310948,"twenty":-60.422571,"median":-13.83181,"eighty":-5.658826,"marketCap":21530015},{"date":"2023-04-28","current":-1.398249,"twenty":-47.962314,"median":-13.730013,"eighty":-5.59802,"marketCap":22963775},{"date":"2023-05-05","current":-1.498124,"twenty":-47.962314,"median":-13.705049,"eighty":-5.49939,"marketCap":24604044},{"date":"2023-05-12","current":-1.558049,"twenty":-47.962314,"median":-13.64563,"eighty":-5.24151,"marketCap":25588206},{"date":"2023-05-19","current":-1.963531,"twenty":-47.962314,"median":-13.355558,"eighty":-3.791935,"marketCap":24056194},{"date":"2023-05-26","current":-1.809834,"twenty":-47.962314,"median":-13.299333,"eighty":-3.683387,"marketCap":22173165},{"date":"2023-06-02","current":-1.797516,"twenty":-46.033619,"median":-13.23074,"eighty":-3.614639,"marketCap":22022260},{"date":"2023-06-09","current":-1.684251,"twenty":-43.485789,"median":-12.981103,"eighty":-3.299851,"marketCap":20634592},{"date":"2023-06-16","current":-1.609276,"twenty":-39.895803,"median":-12.731467,"eighty":-2.015739,"marketCap":19716041},{"date":"2023-06-23","current":-1.446742,"twenty":-38.369814,"median":-12.48183,"eighty":-1.965287,"marketCap":17724753},{"date":"2023-06-30","current":-1.344455,"twenty":-36.826895,"median":-12.48183,"eighty":-1.921295,"marketCap":16471587},{"date":"2023-07-07","current":-1.241901,"twenty":-36.397248,"median":-12.48183,"eighty":-1.877068,"marketCap":15215141},{"date":"2023-07-14","current":-1.204949,"twenty":-33.757987,"median":-12.48183,"eighty":-1.845821,"marketCap":14762426},{"date":"2023-07-21","current":-1.017513,"twenty":-33.635231,"median":-12.357585,"eighty":-1.824236,"marketCap":12466049},{"date":"2023-07-28","current":-0.905985,"twenty":-32.837315,"median":-12.357012,"eighty":-1.794379,"marketCap":11099674},{"date":"2023-08-04","current":-0.900255,"twenty":-31.425617,"median":-11.857738,"eighty":-1.773608,"marketCap":11029470},{"date":"2023-08-11","current":-0.63419,"twenty":-30.638859,"median":-11.386083,"eighty":-1.73785,"marketCap":7769771},{"date":"2023-08-18","current":-0.55807,"twenty":-30.103498,"median":-11.220378,"eighty":-1.68709,"marketCap":7062935},{"date":"2023-08-25","current":-0.523965,"twenty":-29.033151,"median":-11.097077,"eighty":-1.675707,"marketCap":6631311},{"date":"2023-09-01","current":-0.420938,"twenty":-28.224507,"median":-11.097077,"eighty":-1.659207,"marketCap":5327390},{"date":"2023-09-08","current":-0.350246,"twenty":-27.178685,"median":-11.097077,"eighty":-1.647519,"marketCap":4432713},{"date":"2023-09-15","current":-0.343819,"twenty":-25.922457,"median":-10.973777,"eighty":-1.629248,"marketCap":4351379},{"date":"2023-09-22","current":-0.313422,"twenty":-25.608909,"median":-10.850476,"eighty":-1.618329,"marketCap":3966668},{"date":"2023-09-29","current":-0.321326,"twenty":-23.64226,"median":-10.850476,"eighty":-1.601441,"marketCap":4066710},{"date":"2023-10-06","current":-0.289162,"twenty":-22.775869,"median":-10.688976,"eighty":-1.580196,"marketCap":3659632},{"date":"2023-10-13","current":-0.282767,"twenty":-22.573417,"median":-10.456607,"eighty":-1.555984,"marketCap":3578704},{"date":"2023-10-20","current":-0.29562,"twenty":-21.87715,"median":-10.357272,"eighty":-1.530122,"marketCap":3741373},{"date":"2023-10-27","current":-0.411298,"twenty":-20.708929,"median":-10.28233,"eighty":-1.525237,"marketCap":5205388},{"date":"2023-11-03","current":-0.385592,"twenty":-20.392025,"median":-10.008413,"eighty":-1.495062,"marketCap":4880052},{"date":"2023-11-10","current":-0.347032,"twenty":-20.25282,"median":-9.861161,"eighty":-1.453706,"marketCap":4392046},{"date":"2023-11-17","current":-0.527039,"twenty":-20.061981,"median":-9.742695,"eighty":-1.436505,"marketCap":6466068},{"date":"2023-11-24","current":-1.186185,"twenty":-20.052297,"median":-9.704796,"eighty":-1.418894,"marketCap":14552898},{"date":"2023-12-01","current":-0.739897,"twenty":-20.005723,"median":-9.704796,"eighty":-1.398059,"marketCap":9077550},{"date":"2023-12-08","current":-0.734025,"twenty":-19.855784,"median":-9.614269,"eighty":-1.379383,"marketCap":9005506},{"date":"2023-12-15","current":-0.757514,"twenty":-19.851774,"median":-9.529855,"eighty":-1.357844,"marketCap":9293682},{"date":"2023-12-22","current":-0.645942,"twenty":-19.450728,"median":-9.294762,"eighty":-1.3426,"marketCap":7924845},{"date":"2023-12-29","current":-0.734025,"twenty":-19.297293,"median":-9.178577,"eighty":-1.336307,"marketCap":9005506},{"date":"2024-01-05","current":-0.88681,"twenty":-18.799586,"median":-9.116636,"eighty":-1.327539,"marketCap":10879973},{"date":"2024-01-12","current":-0.924547,"twenty":-18.612428,"median":-9.098246,"eighty":-1.320866,"marketCap":11342950},{"date":"2024-01-19","current":-0.793298,"twenty":-18.4748,"median":-9.093511,"eighty":-1.311971,"marketCap":9732698},{"date":"2024-01-26","current":-0.812646,"twenty":-18.270731,"median":-8.999403,"eighty":-1.29484,"marketCap":9970081},{"date":"2024-02-02","current":-0.973886,"twenty":-18.114699,"median":-8.888116,"eighty":-1.287424,"marketCap":11948272},{"date":"2024-02-09","current":-0.838445,"twenty":-18.019487,"median":-8.794971,"eighty":-1.269673,"marketCap":10286591},{"date":"2024-02-16","current":-0.825545,"twenty":-17.817247,"median":-8.794971,"eighty":-1.256593,"marketCap":10128336},{"date":"2024-02-23","current":-0.780398,"twenty":-17.732346,"median":-8.790393,"eighty":-1.250053,"marketCap":9574443},{"date":"2024-03-01","current":-0.780398,"twenty":-17.646021,"median":-8.785645,"eighty":-1.245038,"marketCap":9574443},{"date":"2024-03-08","current":-0.806197,"twenty":-17.646021,"median":-8.666669,"eighty":-1.242787,"marketCap":9890953},{"date":"2024-03-15","current":-1.202078,"twenty":-17.560637,"median":-8.610667,"eighty":-1.232053,"marketCap":12640641},{"date":"2024-03-22","current":-1.061836,"twenty":-17.368294,"median":-8.491696,"eighty":-1.227587,"marketCap":11165900},{"date":"2024-03-28","current":-1.202078,"twenty":-17.227608,"median":-8.487276,"eighty":-1.21683,"marketCap":12640641},{"date":"2024-04-05","current":-1.282217,"twenty":-17.050112,"median":-8.393504,"eighty":-1.215841,"marketCap":13483351},{"date":"2024-04-12","current":-1.151992,"twenty":-16.459254,"median":-8.335718,"eighty":-1.212048,"marketCap":12113948},{"date":"2024-04-19","current":-1.051818,"twenty":-16.10474,"median":-8.21272,"eighty":-1.209834,"marketCap":11060561},{"date":"2024-04-26","current":-1.592754,"twenty":-15.910707,"median":-7.968666,"eighty":-1.204842,"marketCap":16748850},{"date":"2024-05-03","current":-1.151992,"twenty":-15.82702,"median":-7.731497,"eighty":-1.203538,"marketCap":12113948},{"date":"2024-05-10","current":-1.101905,"twenty":-15.82702,"median":-7.634408,"eighty":-1.200338,"marketCap":11587254},{"date":"2024-05-17","current":-1.061836,"twenty":-15.734838,"median":-7.48459,"eighty":-1.18456,"marketCap":11165900},{"date":"2024-05-24","current":-0.858149,"twenty":-15.582152,"median":-7.430234,"eighty":-1.178636,"marketCap":10834083},{"date":"2024-05-31","current":-0.715889,"twenty":-15.563236,"median":-7.382,"eighty":-1.173177,"marketCap":9038058},{"date":"2024-06-07","current":-0.658318,"twenty":-15.563236,"median":-7.319625,"eighty":-1.165754,"marketCap":8311221},{"date":"2024-06-14","current":-0.711685,"twenty":-15.563236,"median":-7.290579,"eighty":-1.161858,"marketCap":8984974},{"date":"2024-06-21","current":-0.630227,"twenty":-15.512687,"median":-7.276703,"eighty":-1.151992,"marketCap":7956573},{"date":"2024-06-28","current":-0.631856,"twenty":-15.351334,"median":-7.261532,"eighty":-1.146431,"marketCap":7977141},{"date":"2024-07-05","current":-0.62594,"twenty":-15.258759,"median":-7.232486,"eighty":-1.131572,"marketCap":7902447},{"date":"2024-07-12","current":-0.703024,"twenty":-15.199238,"median":-7.174394,"eighty":-1.12194,"marketCap":8875638},{"date":"2024-07-15","current":-0.678244,"twenty":-15.199238,"median":-7.116302,"eighty":-1.119798,"marketCap":8562788},{"date":"2024-08-02","current":-0.716281,"twenty":-14.887513,"median":-6.941989,"eighty":-1.109939,"marketCap":9043003},{"date":"2024-08-09","current":-0.651797,"twenty":-14.669052,"median":-6.792928,"eighty":-1.091888,"marketCap":8228892},{"date":"2024-08-16","current":-0.751707,"twenty":-14.498482,"median":-6.738702,"eighty":-1.08187,"marketCap":8549966},{"date":"2024-08-23","current":-0.748193,"twenty":-14.327911,"median":-6.622518,"eighty":-1.078179,"marketCap":8510005},{"date":"2024-08-30","current":-0.721532,"twenty":-14.296916,"median":-6.562136,"eighty":-1.072328,"marketCap":8206761},{"date":"2024-09-06","current":-0.68602,"twenty":-14.296916,"median":-6.469219,"eighty":-1.069821,"marketCap":7802835},{"date":"2024-09-13","current":-0.727328,"twenty":-14.296916,"median":-6.411345,"eighty":-1.061836,"marketCap":8272684},{"date":"2024-09-20","current":-0.696727,"twenty":-14.296916,"median":-6.353237,"eighty":-1.054133,"marketCap":7924624},{"date":"2024-09-27","current":-0.695504,"twenty":-14.296916,"median":-6.321565,"eighty":-1.044289,"marketCap":7910709},{"date":"2024-10-04","current":-0.671793,"twenty":-14.118204,"median":-6.222154,"eighty":-1.036389,"marketCap":7641025},{"date":"2024-10-11","current":-0.50013,"twenty":-14.066248,"median":-6.067323,"eighty":-1.01984,"marketCap":5688519},{"date":"2024-10-18","current":-0.576109,"twenty":-14.066248,"median":-5.964847,"eighty":-1.014835,"marketCap":6552704},{"date":"2024-10-25","current":-0.757678,"twenty":-13.83181,"median":-5.814279,"eighty":-0.991815,"marketCap":8617878},{"date":"2024-10-31","current":-0.758731,"twenty":-13.730013,"median":-5.719235,"eighty":-0.980335,"marketCap":8629864},{"date":"2024-11-08","current":-0.571578,"twenty":-13.730013,"median":-5.630104,"eighty":-0.95093,"marketCap":6501164},{"date":"2024-11-15","current":-0.58064,"twenty":-13.64563,"median":-5.578452,"eighty":-0.920835,"marketCap":6604243},{"date":"2024-11-22","current":-0.799583,"twenty":-13.418762,"median":-5.497016,"eighty":-0.900947,"marketCap":6591059},{"date":"2024-11-29","current":-0.787271,"twenty":-13.355558,"median":-5.239709,"eighty":-0.895748,"marketCap":6489564},{"date":"2024-12-06","current":-0.794995,"twenty":-13.233835,"median":-3.78108,"eighty":-0.88234,"marketCap":6553235},{"date":"2024-12-13","current":-0.764989,"twenty":-13.105921,"median":-3.672532,"eighty":-0.851444,"marketCap":6305897},{"date":"2024-12-20","current":-0.769,"twenty":-12.89,"median":-3.527801,"eighty":-0.838445,"marketCap":6338957},{"date":"2024-12-27","current":-0.830348,"twenty":-12.631501,"median":-3.093611,"eighty":-0.825442,"marketCap":6844653},{"date":"2025-01-03","current":-0.952598,"twenty":-12.48183,"median":-2.023095,"eighty":-0.825442,"marketCap":7852372},{"date":"2025-01-10","current":-0.793212,"twenty":-12.48183,"median":-1.965726,"eighty":-0.824584,"marketCap":6538542},{"date":"2025-01-17","current":-0.818613,"twenty":-12.48183,"median":-1.915211,"eighty":-0.816226,"marketCap":6747922},{"date":"2025-01-24","current":-0.79247,"twenty":-12.48183,"median":-1.86954,"eighty":-0.811335,"marketCap":6532419},{"date":"2025-01-31","current":-0.772417,"twenty":-12.48183,"median":-1.845312,"eighty":-0.806197,"marketCap":6367119},{"date":"2025-02-07","current":-0.680321,"twenty":-12.48183,"median":-1.822285,"eighty":-0.800781,"marketCap":5607963},{"date":"2025-02-14","current":-0.62239,"twenty":-12.48183,"median":-1.794164,"eighty":-0.798943,"marketCap":5130429},{"date":"2025-02-21","current":-0.868969,"twenty":-12.48183,"median":-1.774601,"eighty":-0.794876,"marketCap":7163009},{"date":"2025-02-28","current":-1.185362,"twenty":-12.48183,"median":-1.738663,"eighty":-0.794876,"marketCap":9771079},{"date":"2025-03-07","current":-0.94517,"twenty":-12.48183,"median":-1.686929,"eighty":-0.794817,"marketCap":7791150},{"date":"2025-03-14","current":-1.021967,"twenty":-12.48183,"median":-1.674611,"eighty":-0.794817,"marketCap":8424189},{"date":"2025-03-21","current":-0.987802,"twenty":-12.48183,"median":-1.658971,"eighty":-0.794817,"marketCap":8142566},{"date":"2025-03-28","current":-1.186848,"twenty":-12.48183,"median":-1.64007,"eighty":-0.794817,"marketCap":9783324},{"date":"2025-04-04","current":-1.358413,"twenty":-12.48183,"median":-1.633375,"eighty":-0.794817,"marketCap":11197559},{"date":"2025-04-11","current":-1.559687,"twenty":-12.48183,"median":-1.622615,"eighty":-0.794876,"marketCap":12856684},{"date":"2025-04-17","current":-2.422481,"twenty":-12.48183,"median":-1.616463,"eighty":-0.794876,"marketCap":11877127},{"date":"2025-04-25","current":-2.795995,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":13708421},{"date":"2025-05-02","current":-5.324769,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":15499093},{"date":"2025-05-09","current":-6.823976,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19862916},{"date":"2025-05-16","current":-6.668915,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19411570},{"date":"2025-05-23","current":-6.755518,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19663651},{"date":"2025-05-30","current":-7.816302,"twenty":-12.357356,"median":-1.615552,"eighty":-0.794817,"marketCap":22751332},{"date":"2025-06-06","current":-8.374609,"twenty":-12.307084,"median":-1.615552,"eighty":-0.794817,"marketCap":24376428},{"date":"2025-06-13","current":-10.328685,"twenty":-11.690443,"median":-1.615552,"eighty":-0.794817,"marketCap":30064261}],"updateTime":1750062983041}}}